Federal Policies Affecting The Cost and Availability of New Pharmaceuticals

This report by Michael Gluck of the Georgetown University Institute for Health Care Research and Policy examines several ways in which the federal government influences the availability and cost of prescription drugs, including 1) intellectual property protection the laws and policies which regulate and influence patents and generic competition (include the Hatch-Waxman Act), 2) federal support for drug research and development, 3) federal tax subsidies through various tax credits available to pharmaceutical firms, and 4) reimportation from other countries of drugs produced in the US. July, 2002.